TB or not TB: Is Emergent‘s vaccine the solution?

MVA85A, the leading investigational vaccine against TB, has failed to replicate early promising efficacy seen in adults in a new Phase IIb study in infants published this week in The Lancet. But despite the disappointment, experts say this should not spell the end for the product, and the study should provide useful pointers for planning other trials and vaccination strategies.